Total amount raised
$2.5 Billions
Latest funding date
10/01/2024
Location
Resilience is making strides in the biomanufacturing sector, offering comprehensive services in biologics, vaccines, nucleic acids, cell therapy, and gene therapy. The company is focused on revolutionizing the production, funding, and scaling of novel medicines through innovative approaches and strategic partnerships.
Recent developments include a significant partnership with JobsOhio, aimed at expanding Resilience's operations in Blue Ash, OH. This collaboration underscores the company's commitment to enhancing its biomanufacturing capabilities and supporting the development of groundbreaking therapies.
What Is Resilience?
National Resilience, Inc. is a biomanufacturing innovation partner specializing in CDMO (Contract Development and Manufacturing Organization) services. The company focuses on producing biologics, vaccines, nucleic acids, cell therapy, and gene therapy, leveraging advanced technologies and a network of high-tech facilities across North America.
Resilience aims to revolutionize the production of complex medicines, offering end-to-end drug substance and drug product manufacturing solutions. Their mission includes broadening access to these medicines and protecting biopharmaceutical supply chains against disruption, providing scalable solutions for small to mid-sized biotech companies.
How Much Funding Has Resilience Raised?
- Series A
- Amount Raised: $50M
- Date: October 2020
- Lead Investors: Magnetic Ventures
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To establish initial biomanufacturing capabilities and support early-stage development.
- Series B
- Amount Raised: $750M
- Date: November 2020
- Lead Investors: 8VC, ARCH Venture Partners
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To scale up biomanufacturing operations and expand production capabilities.
- Series C
- Amount Raised: $600M
- Date: August 2021
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To further expand manufacturing capacity and enhance technological infrastructure.
- Series C
- Amount Raised: $80M
- Date: November 2021
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support ongoing expansion and operational scaling.
- Series D
- Amount Raised: $625M
- Date: June 2022
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To accelerate growth and enhance biomanufacturing capabilities.
- Private Equity Round
- Amount Raised: Not publicly disclosed
- Date: January 2023
- Lead Investors: Mubadala
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To secure strategic investments for long-term growth and innovation.
- Debt Financing
- Amount Raised: $410M
- Date: March 2023
- Lead Investors: U.S. Department of Defense, U.S. International Development Finance Corp
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To establish an end-to-end biomanufacturing capacity and strengthen the domestic biomanufacturing sector.
- Grant
- Amount Raised: $17.5M
- Date: October 2024
- Lead Investors: Administration for Strategic Preparedness and Response
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand the manufacturing of critical medicine components and secure the pharmaceutical supply chain.
Total Amount Raised: $2.5325B
Current Valuation: Not publicly disclosed
Key Investors
- Administration for Strategic Preparedness and Response (ASPR)
- Details: ASPR is a division of the U.S. Department of Health and Human Services focused on preparing for and responding to public health emergencies. It provides funding to support the domestic production of critical pharmaceutical ingredients.
- Investment Focus Areas: Public health preparedness and response, domestic production of key starting materials, active pharmaceutical ingredients (APIs).
- Notable Investments: Nearly $17.5 million in funding to Resilience for domestic production of APIs.
- U.S. Department of Defense
- Details: The U.S. Department of Defense is a federal agency responsible for coordinating and supervising all agencies and functions of the government related to national security and the armed forces.
- Investment Focus Areas: National security, defense technology, biomanufacturing.
- Notable Investments: $410 million in debt financing to Resilience for establishing end-to-end biomanufacturing capacity.
- U.S. International Development Finance Corp
- Details: The U.S. International Development Finance Corp is a government agency that provides financing for development projects in emerging markets to advance economic development and U.S. foreign policy interests.
- Investment Focus Areas: Economic development, healthcare, infrastructure.
- Notable Investments: $410 million in debt financing to Resilience for biomanufacturing capacity.
- 8VC
- Details: 8VC is a venture capital firm that invests in early-stage technology companies. It focuses on building and supporting transformative companies across various sectors.
- Investment Focus Areas: Technology, healthcare, logistics.
- Notable Investments: $750 million in Series B funding to Resilience.
- ARCH Venture Partners
- Details: ARCH Venture Partners is a venture capital firm that invests in early-stage biotechnology companies. It focuses on innovative technologies and scientific advancements.
- Investment Focus Areas: Biotechnology, life sciences, healthcare.
- Notable Investments: $750 million in Series B funding to Resilience.
What's Next for Resilience?
Resilience is poised to capitalize on significant opportunities in the biomanufacturing sector, particularly through the expansion of domestic production for critical pharmaceutical ingredients. With nearly $17.5 million in new funding from the U.S. Department of Health and Human Services, the company aims to enhance its cGMP production capabilities and secure the pharmaceutical supply chain. This collaboration with Aralez Bio to leverage advanced biocatalysis technology underscores the potential for substantial growth.
Future fundraising opportunities are likely to arise from additional public-private partnerships and government grants, as well as private equity investments. These funds will be crucial for scaling up manufacturing operations and meeting FDA requirements to become an approved domestic API supplier. However, Resilience may face challenges such as regulatory compliance, ensuring consistent quality, and navigating the complexities of public-private partnerships. Despite these hurdles, the company's strategic initiatives and industry trends suggest a promising path forward.
Use Clay to Get Funding Data
Sales professionals, take advantage of Clay's platform to access comprehensive fundraising data on companies like Resilience and gather other critical business insights. Sign up for free today to unlock valuable information that can drive your sales strategy and help you stay ahead in the competitive market.
